Spyre Therapeutics, Inc. SYRE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s EPS (diluted)?
- Spyre Therapeutics, Inc. (SYRE) reported EPS (diluted) of -$0.74 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Spyre Therapeutics, Inc.'s EPS (diluted) decreased by 23.3% year-over-year, from -$0.60 to -$0.74.
- What is the long-term trend for Spyre Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s EPS (diluted) has grown at a -57.1% compound annual growth rate (CAGR), from -$25.02 to -$1.98.
- What does EPS (diluted) mean?
- The profit per share calculated as if all potential shares that could be created were already issued.
- How do you interpret EPS (diluted)?
- A smaller gap between basic and diluted EPS suggests a lower potential for future share dilution, whereas a significant gap indicates a large overhang of convertible instruments.
- How does EPS (diluted) compare across companies?
- In the biotech sector, diluted EPS is often identical to basic EPS when the company is reporting a net loss, as the inclusion of dilutive securities would be anti-dilutive.